Form 4: Collegium Pharmaceutical EVP and General Counsel Sells Shares Under 10b5-1 Plan

Shirley R. Kuhlmann, EVP and General Counsel of Collegium Pharmaceutical, sold shares of common stock on June 3, 2024, under a pre-arranged Rule 10b5-1 trading plan.

Summary

• Shirley R. Kuhlmann, the EVP and General Counsel of Collegium Pharmaceutical, sold shares of the company's common stock on June 3, 2024.
• The sales were executed under a Rule 10b5-1 trading plan adopted on February 26, 2024.
• A total of 25,000 shares were sold in multiple transactions at weighted average prices of $32.5484 and $33.22.
• Following the reported transactions, Kuhlmann beneficially owns 139,409 shares of Collegium Pharmaceutical.
• The reporting person will provide full information regarding the number of shares sold at each separate price within the specified ranges upon request.

Sentiment

Score: 5

Explanation: The document is a standard regulatory filing detailing share sales by an executive. It doesn't inherently convey positive or negative sentiment.

Industry Context

This filing is a routine disclosure of insider trading activity. It is common for executives to use 10b5-1 plans to sell shares over time to avoid accusations of trading on inside information.

Stakeholder Impact

• The share sale could have a minor negative impact on shareholder sentiment, although the use of a 10b5-1 plan mitigates concerns about insider trading.

Key Dates